Pharmacokinetics & Drug Response

Abstractions about how the body processes and responds to drugs — absorption, clearance, and metabolic pathways that set exposure; receptor-level potency, efficacy, and antagonism that set effect; and failure modes from adverse reactions to resistance selection and polypharmacy.

19 abstractions in this family — domain-specific abstractions that sit near one another in structural-signature space (k-means over structural-signature embeddings). Each is shown with its short description.

• Absorption Phase — Carve out the rising limb of a drug's plasma curve as a distinct stage with its own two determinants — how fast the dose crosses into circulation and how much survives to arrive — so before-circulation variability is not confused with what happens after.
• Adverse Drug Event — Harm to a patient caused by the pharmacology of a drug rather than the process of delivering it — bracketing mechanistically unlike injuries under one causal structure so the prescribing question becomes a benefit-to-harm ratio, not a binary safety verdict.
• Adverse Drug Reaction — Classify an unintended, harmful response arising under correct drug use — not through any administration error — by an ABCDEF taxonomy whose pivotal dose-related-versus-idiosyncratic split reads off predictability, remedy, and whether trials could ever have caught it.
• Antimicrobial Resistance Selection — Read the erosion of an antimicrobial's effectiveness as directional selection — the agent's use prunes susceptible organisms and spares pre-existing resistant variants — so a failing protocol reports a shifted population, not a degraded drug, and the user of the agent is the source of the pressure.
• Clearance — Express the body's power to eliminate a substance as the virtual volume of plasma fully cleared per unit time (Cl = elimination rate / concentration), a concentration-independent capacity that sums additively across organs.
• Efficacy — Separate the maximum effect a drug can produce at its target under full engagement (the ceiling, E_max) from the dose needed to approach it (potency, EC50), rooting that ceiling in the agent's intrinsic activity so a ceiling problem cannot be fixed by escalation.
• Elimination Pathway — Classify a drug or toxin by the dominant biochemical route through which the body removes it — hepatic metabolism, renal excretion, or a minor exit — so that clearance rate, interaction risks, and toxicity failure modes can be read off the route rather than memorized per substance.
• Enzyme Induction — The phenomenon in which a xenobiotic binds a nuclear receptor and raises transcription of specific metabolizing enzymes, enlarging the catalytic pool over days so it clears itself and every co-substrate sharing those isoforms faster.
• Enzyme Inhibition — A small molecule slows an enzyme by occupying or distorting its catalytic site, and the binding mode it uses fixes how reversible, surmountable, and durable the block will be.
• First-Pass Metabolism — Explain why an oral drug's dose depends on its route by tracking one obligate pre-systemic compartment — the splanchnic-hepatic transit — and the extraction ratio E that sets oral bioavailability as F = 1 − E.
• Idiosyncratic Reaction — Classify a rare drug harm as a distinct causal category — dose-independent, qualitatively different in kind, and confined to a small biologically-defined susceptible tail — so it is understood not as too-much-drug but as uniform exposure meeting a heterogeneous responder population.
• Inverse Agonist — A ligand that binds a receptor with constitutive activity and selectively stabilizes its inactive conformation, driving output below the unliganded baseline — occupying the negative end of a signed efficacy axis, distinct from an antagonist that merely blocks.
• Metabolic Inactivation — The enzymatic transformation of a biologically active substance into a less-active product that ends its effect — organised into phase-I functionalisation and phase-II conjugation, it sets a drug's half-life and makes interactions and variability a bookkeeping question over shared enzymes.
• Partial Agonist — A ligand that binds and activates a receptor but with intrinsic efficacy between zero and one, so even at full occupancy it produces a submaximal response — acting as an agonist when alone and a functional antagonist when a full agonist is present.
• Pharmacodynamic Antagonism — Diagnose why two co-administered drugs blunt each other by locating the opposition at the receptor or effector rather than at the concentration layer, then classify its binding geometry to read off whether more dose can overcome it.
• Pharmacokinetic Interaction — Locate a drug-interaction failure at the exposure layer — one substance altering another's absorption, distribution, metabolism, or excretion so its concentration-time profile shifts at an unchanged dose — rather than as opposition at a shared receptor.
• Polypharmacy — Shift the unit of clinical attention from the single prescription to the whole regimen, sorting the combined risk of concurrent drugs into three channels — pharmacokinetic collisions, pharmacodynamic summation, and the prescribing cascade — under one appropriate-versus-problematic binary.
• Potency — Quantify how much drug a given effect costs by reading one coordinate off the dose-response curve: the dose that produces half the maximal response (the ED50), so a lower value means less drug suffices.
• Therapeutic Duplication — The medication-safety failure where uncoordinated prescribers each place a defensible order that lands on the same pharmacologic target, so additive exposure overruns the therapeutic window — a harm that lives in the set of orders, not in any single one.